L-NG-monomethyl Arginine (L-NMMA)
PreclinicalSmall molecule
L-NG-monomethyl Arginine (L-NMMA) is one of 6 small molecule programs targeting Endothelial Function. It is currently in Preclinical.
1
Indications
3
Total Trials
0
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in Endothelial Function
#DrugCompanyPhaseTrials
1Estrace
Novo NordiskApproved
Nulojix
Bristol-Myers SquibbApproved
Azulfidine
PfizerPreclinical
Slow Sodium
SSt George's, University of London
Preclinical
Viagra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
L-NG-monomethyl Arginine (L-NMMA)
EEmory University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Endothelial Function1 trial
Endothelial Function in Lower Extremity Bypass Grafts
Completed·—·N/A·NCT00759707·19 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- EEmory University